Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma

References

• Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124–133.
   PubMed Web of Science ®Google Scholar
• National Institute of Health Consensus Development Conference statement: Neurofibrmatosis. Arch Neurol Chicago. 1988;45:575–578.
   PubMed Web of Science ®Google Scholar
• Korf BR. Plexiform neurofibromas. Am J Med Genet. 1999;89(1):31–37.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration (FDA). FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas.(Drug approvals and database). 10th April, 2020; [cited 2021 Mar 06]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/.
   Google Scholar
• Gutmann DH, Blakeley JO, Korf BR, et al. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22(4):443–462.
   PubMed Web of Science ®Google Scholar
• Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015;15(5):290–301.
   PubMed Web of Science ®Google Scholar
• Hutchinson L. Targeted therapies: Selumetinib MEKing differences in NF1. Nat Rev Clin Oncol. 2017;14(3):140
   Web of Science ®Google Scholar
• Holt SV, Logié A, Odedra R, et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer. 2012;106(5):858–866.
   PubMed Web of Science ®Google Scholar
• Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020; [cited 2021 Mar 06]. Available from: www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
   Google Scholar
• Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61(1):1–14.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Dombi E, Gillespie A, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyl transferase inhibitortipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014;16(5):707–718.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598–1602.
   PubMed Web of Science ®Google Scholar
• Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596–603.
   PubMed Web of Science ®Google Scholar
• Weiss B, Widemann BC, Wolters P, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014;61(6):982–986.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Dombi E, Steinberg SM, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2016;19(2):289–297.
   Web of Science ®Google Scholar
• Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13(12):1218–1224.
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Bekaii-Saab T. Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(1):111–123.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139–2146.
   PubMed Web of Science ®Google Scholar
• Jousma E, Rizvi TA, Wu J, et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer. 2015;62(10):1709–1716.
   PubMed Web of Science ®Google Scholar
• Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550–2560.
   PubMed Web of Science ®Google Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430–1442.
   PubMed Web of Science ®Google Scholar
• Espírito Santo V, Passos J, Nzwalo H, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. 2020;147(2):459–463.
   PubMed Web of Science ®Google Scholar
• Hua C, Zehou O, Ducassou S, et al. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas. Pediatrics. 2014;133(6):e1792–e1797.
   PubMed Web of Science ®Google Scholar
• Jackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020;8(1):vdaa095.
   Google Scholar
• Beert E, Brems H, Daniels B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011;50(12):1021–1032.
   PubMed Web of Science ®Google Scholar